Leading Irish-owned digital healthcare company, patientMpower, is building on recent U.S. market success and has announced further expansion plans to aid those suffering from chronic illnesses with new developments in the area of kidney disease. According to the Centers for Disease Control and Prevention, about 37 million adults in the United States are estimated to have chronic kidney disease. In some states, the illness has become so prevalent that they have created statewide task forces dedicated specifically to preventing, treating, and educating the public about the disease.
patientMpower provides award-winning technology solutions for people living with long-term illnesses. Its solutions enable patients to better manage their care remotely and provide data insights for healthcare providers and researchers to improve treatments. Following the recent announcement of major funding, in the form of the Irish Government’s Disruptive Technologies Innovation Fund, patientMpower plans to expand into chronic kidney disease with the development of a new artificial intelligence medical device for kidney dialysis.
The kidney dialysis solution will build on existing patientMpower technology, which allows patients to monitor their health (e.g. weight, lung function, and blood pressure) and manage their medications all through a patient-facing software application. EMR connectivity lets healthcare professionals see health data in real-time whilst smart alerts trigger them to intervene when necessary. patientMpower’s technology is already being used by the Transplant Institute at NYU Langone to enable lung transplant recipients to be monitored from their own homes.
“Our solution was developed to make life a little easier for people fighting through difficult conditions,” said Eamonn Costello, Chief Executive Officer, patientMpower. “Our technology empowers patients to better manage their health and provides healthcare professionals with insights to improve outcomes.”